Recombinant anti-CD20 monoclonal antibody (Geneky Biotech)

重组抗CD20单抗（成都金凯生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant anti-CD20 monoclonal antibody (Geneky Biotech)
Drug Alias Name重组抗CD20单抗注射液（成都金凯生物）重组抗CD20单克隆抗体 注射液（成都金凯生物）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsArthritis, RheumatoidLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesXinlitai (Chengdu) Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Genemen Biotech Co LtdTianjin Bogene Technology Co LtdXinlitai (Chengdu) Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A